newsfilter
← Latest News
GlobeNewswire·

Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting

  • Caribou Biosciences announced that clinical abstracts for vispa-cel and CB-011 were accepted for two oral presentations & one poster presentation at the 2026 ASH Annual Meeting.
  • The 2026 ASH Annual Meeting is scheduled to be held December 12-15, 2026, in New Orleans, Louisiana.
  • These presentations will share clinical findings prior to Caribou's announcement regarding plans to explore strategic alternatives & discontinue development of the two allogeneic CAR-T cell therapy programs.
  • The discontinuation of vispa-cel (for r/r B cell non-Hodgkin lymphoma) & CB-011 (for r/r multiple myeloma) is attributed to the current financing environment for allogeneic CAR-T cell therapies.
  • Oral presentation 1 features data from the ANTLER trial on vispa-cel presented by Mehdi Hamadani on Monday, December 14, 2026.
  • Oral presentation 2 features data from the CaMMouflage trial on CB-011 presented by Adriana Rossi on Saturday, December 12, 2026.
  • Poster presentation details vispa-cel outcomes in patients with large B cell lymphoma presented by Mohamad Cherry on Sunday, December 13, 2026.
  • Abstracts became available on the 2026 ASH Annual Meeting website on November 4, 2026.
  • Vispa-cel is an allogeneic anti-CD19 CAR-T therapy with a PD-1 knockout strategy & has received FDA RMAT, Fast Track, & Orphan Drug designations.
  • CB-011 is an allogeneic anti-BCMA CAR-T therapy utilizing an immune cloaking strategy with a B2M knockout & has received FDA RMAT, Fast Track, & Orphan Drug designations.
  • On October 6, 2026, Caribou announced it would explore strategic alternatives to maximize stockholder value, including the planned discontinuation of clinical trials for vispa-cel & CB-011.